Related Experiment Video
Updated: Aug 9, 2025
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
9.7K
Superficial soft tissue sarcomas: 10‑year survival outcomes
Maria Tolia1, Areti Gkantaifi2, Larry Hayward3
1Department of Radiotherapy, University Hospital/Medical School, University of Crete, Vassilika, 71110 Crete, Greece.
Oncology Letters
|February 23, 2023
Summary
This study on superficial soft tissue sarcomas (SSTS) found that increasing age significantly increases mortality risk. Optimal management of these rare tumors requires multidisciplinary teams and consensus guidelines.
Area of Science:
- Oncology
- Surgical Pathology
- Epidemiology
Background:
- Cutaneous sarcomas are rare, diverse mesenchymal tumors.
- Superficial soft tissue sarcomas (SSTS) represent a specific subtype requiring dedicated management strategies.
- Understanding prognostic factors is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the management and outcomes of patients with SSTS.
- To identify key prognostic factors for overall survival (OS) and local relapse-free survival.
- To analyze single-center data for service evaluation.
Main Methods:
- Retrospective analysis of 66 patients with SSTS treated surgically.
- Data collection included demographics, tumor specifics, and treatment details.
- Statistical analysis involved Kaplan-Meier curves, mortality rate estimation, and Cox regression.
Main Results:
- The mean estimated OS time was 57.2 months.
- Mortality risk increased by 7.3% for each additional year of life.
- No independent variables statistically significantly predicted local relapse recurrence time.
Conclusions:
- Age is a significant independent predictor of mortality in SSTS patients.
- Effective management of rare SSTS necessitates a multidisciplinary team approach.
- Consensus guidelines are vital for informed decision-making in SSTS treatment.
